TY - JOUR
T1 - Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
AU - Johnson, Faye M.
AU - Kurie, Jonathan M.
AU - Peeples, Beverly O.
AU - Pisters, Katherine M.
AU - Fossella, Frank V.
AU - Papadimitrakopoulou, Vassiliki A.
AU - Blumenschein, George R.
AU - Komaki, Ritsuko
AU - Glisson, Bonnie S.
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2003/7
Y1 - 2003/7
N2 - Irinotecan (CPT-11, Camptosar) has significant activity in small-cell lung cancer. In addition, preclinical models have demonstrated synergy between irinotecan and two standard front-line drugs for small-cell lung cancer: cisplatin and etoposide; phase III data also show significant survival benefit for irinotecan/cisplatin compared to standard treatment. These data suggest a potential clinical advantage to combining etoposide, cisplatin, and irinotecan as first-line therapy for small-cell lung cancer. The purpose of this phase I study was to establish if alternating weekly therapy with irinotecan/cisplatin and etoposide/cisplatin was tolerated and to determine the maximum tolerated dose of these agents in patients with small-cell lung cancer. Patients generally tolerated the weekly alternating chemotherapy with irinotecan/cisplatin and etoposide/cisplatin well, and this combination possessed significant antitumor activity in small-cell lung cancer.
AB - Irinotecan (CPT-11, Camptosar) has significant activity in small-cell lung cancer. In addition, preclinical models have demonstrated synergy between irinotecan and two standard front-line drugs for small-cell lung cancer: cisplatin and etoposide; phase III data also show significant survival benefit for irinotecan/cisplatin compared to standard treatment. These data suggest a potential clinical advantage to combining etoposide, cisplatin, and irinotecan as first-line therapy for small-cell lung cancer. The purpose of this phase I study was to establish if alternating weekly therapy with irinotecan/cisplatin and etoposide/cisplatin was tolerated and to determine the maximum tolerated dose of these agents in patients with small-cell lung cancer. Patients generally tolerated the weekly alternating chemotherapy with irinotecan/cisplatin and etoposide/cisplatin well, and this combination possessed significant antitumor activity in small-cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0142058818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142058818&partnerID=8YFLogxK
M3 - Article
C2 - 12886869
AN - SCOPUS:0142058818
SN - 0890-9091
VL - 17
SP - 17
EP - 21
JO - Oncology (Williston Park, N.Y.)
JF - Oncology (Williston Park, N.Y.)
IS - 7 Suppl 7
ER -